ARCA hires new VP to market heart failure drug
ARCA biopharma, a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, has appointed James Carr, PharmD, as VP of marketing. 

In the newly created position, Carr will define and execute marketing programs to support the company’s product candidate, Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator in late-stage development for heart failure, according to the Broomfiled, Colo.-based company.

Carr joins ARCA from Anesiva, where he served as VP of marketing for pain management products since 2004. ARCA said he was responsible for the development and launch teams for Zingo, a rapid acting topical anesthetic. Prior to Anesiva, Carr was with GlaxoSmithKline for eight years, where he led the launch for the post-myocardial infarction indication for Coreg (carvedilol), a heart failure treatment.